BRITTANY BOWERMAN: Open Payments
NPI 1760124747 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$876 in 13 payments from 5 companies in 2025. Trend: 2023 $149 · 2024 $632 · 2025 $876
Food & beverage: $876
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 6 | $332 |
| ACADIA Pharmaceuticals Inc | 4 | $205 |
| Amgen Inc. | 1 | $120 |
| ABBVIE INC. | 1 | $114 |
| Otsuka America Pharmaceutical, Inc. | 1 | $104 |
Products named: INGREZZA, NUPLAZID, VRAYLAR, REXULTI.
Industry payments across NE — which companies pay providers there.
